Rossi L, Serafini S, Cenerini L, Picardi F, Bigi L, Panzani I, Magnani M
Istituto di Chimica Biologica G. Fornaini, Università degli Studi di Urbino, Via Saffi 2, 61029 Urbino (PU), Italy.
Biotechnol Appl Biochem. 2001 Apr;33(2):85-9. doi: 10.1042/ba20000087.
Human erythrocytes from ten patients with chronic obstructive pulmonary disease (COPD) were loaded with increasing amounts of dexamethasone 21-phosphate and were re-infused into the original donors. Drug-loaded erythrocytes acted as circulating bioreactors, converting the non-diffusible dexamethasone 21-phosphate into the diffusible dexamethasone. Pharmacokinetic analyses on these patients showed that a single administration of drug-loaded erythrocytes was able to maintain detectable dexamethasone concentrations in blood for up to seven days. This continuous release of dexamethasone was paralleled by the suspension of beta2-agonist and oral corticosteroid treatments by all of the patients. Thus dexamethasone 21-phosphate-loaded erythrocytes are safe carriers for corticosteroid analogues and are a useful alternative to frequent oral or inhaled drugs in elderly patients with COPD.
从十名慢性阻塞性肺疾病(COPD)患者采集的人红细胞被装载了越来越多的地塞米松21 - 磷酸,然后重新输回给原来的捐赠者。载药红细胞充当循环生物反应器,将不可扩散的地塞米松21 - 磷酸转化为可扩散的地塞米松。对这些患者的药代动力学分析表明,单次注射载药红细胞能够在血液中维持可检测到的地塞米松浓度长达七天。地塞米松的这种持续释放与所有患者停用β2激动剂和口服皮质类固醇治疗同时发生。因此,装载地塞米松21 - 磷酸的红细胞是皮质类固醇类似物的安全载体,对于老年COPD患者来说,是频繁口服或吸入药物的一种有用替代方法。